Assessment of the efficacy and safety of lenvatinib for the treatment of radioiodine-refractory differentiated thyroid cancer in real-life practice in Russia

被引：0
|
作者：
Borodavina, E. [1 ]
Isaev, P. [1 ]
Shurinov, A. [1 ]
Krylov, V. [1 ]
机构：
[1] A Tsyb Med Radiol Res Ctr, Radionuclide Therapy Dept, Obninsk, Russia
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.1411
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1923P
引用
下载
收藏
页码：S1089 / S1090
页数：2
相关论文
共 50 条
  • [31] Late toxicities burden in patients with radioiodine-refractory differentiated thyroid cancer treated with lenvatinib
    F. Platini
    S. Cavalieri
    S. Alfieri
    C. Bergamini
    C. Resteghini
    A. Bottiglieri
    E. Colombo
    L. Mazzeo
    L. Licitra
    B. Paolini
    E. Seregni
    L. D. Locati
    Endocrine, 2021, 73 : 641 - 647
  • [32] Low Dose of Lenvatinib Treatment for Patients of Radioiodine-Refractory Differentiated Thyroid Carcinoma - A Real-World Experience
    Jiang, He-Jiun
    Chang, Yen-Hsiang
    Chen, Yen-Hao
    Wu, Che-Wei
    Wang, Pei-Wen
    Hsiao, Pi-Jung
    CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 7139 - 7148
  • [33] Real-World Data for Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer (RELEVANT): A Retrospective Multicentric Analysis of Clinical Practice in Austria
    Rendl, G.
    Sipos, B.
    Becherer, A.
    Sorko, S.
    Trummer, C.
    Raderer, M.
    Hitzl, W.
    Ardelt, M.
    Gallowitsch, H. J.
    Pirich, C.
    INTERNATIONAL JOURNAL OF ENDOCRINOLOGY, 2020, 2020
  • [34] PHARMACOLOGICAL AND CLINICAL PROFILE OF LENVATINIB (E-7080) IN THE TREATMENT OF ADVANCED, RADIOIODINE-REFRACTORY, DIFFERENTIATED THYROID CANCER
    Hegazi, M.
    Azadi, A.
    Jain, D.
    Redman, R.
    Perez, C. A.
    DRUGS OF TODAY, 2015, 51 (12) : 689 - 694
  • [35] Treatment of Patients with Radioiodine-Refractory, differentiated Thyroid Cancer A Consensus Statement
    Lindner, C.
    Dierneder, J.
    Pall, G.
    Pirich, C.
    Hoffmann, M.
    Raderer, M.
    Becherer, A.
    Niederle, B.
    Lipp, R.
    Lind, P.
    Gallowitsch, H.
    Romeder, F.
    Virgolini, I.
    NUKLEARMEDIZIN-NUCLEAR MEDICINE, 2015, 54 (03): : 125 - 130
  • [36] A Randomized, Phase III Study of Lenvatinib in Chinese Patients with Radioiodine-Refractory Differentiated Thyroid Cancer
    Zheng, Xiangqian
    Xu, Zhengang
    Ji, Qinghai
    Ge, Minghua
    Shi, Feng
    Qin, Jianwu
    Wang, Feng
    Chen, Guang
    Zhang, Yuan
    Huang, Rui
    Tan, Jian
    Huang, Tao
    Li, Sijin
    Lv, Zhongwei
    Lin, Yansong
    Guo, Zhuming
    Kubota, Tomoki
    Suzuki, Takuya
    Ikezawa, Hiroki
    Gao, Ming
    CLINICAL CANCER RESEARCH, 2021, 27 (20) : 5502 - 5509
  • [37] Baseline Tumour Size as a Prognostic Factor for Radioiodine-refractory Differentiated Thyroid Cancer Treated With Lenvatinib
    Fukuda, Naoki
    Toda, Kazuhisa
    Ohmoto, Akihiro
    Wang, Xiaofei
    Hayashi, Naomi
    Urasaki, Tetsuya
    Sato, Yasuyoshi
    Nakano, Kenji
    Ono, Makiko
    Tomomatsu, Junichi
    Mitani, Hiroki
    Takahashi, Shunji
    ANTICANCER RESEARCH, 2021, 41 (03) : 1683 - 1691
  • [38] Lenvatinib for the treatment of radioiodine-refractory differentiated thyroid carcinoma: a systematic review and indirect comparison with sorafenib
    Kawalec, Pawel
    Malinowska-Lipien, Iwona
    Brzostek, Tomasz
    Kozka, Maria
    EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (12) : 1303 - 1309
  • [39] Correlation of Performance Status and Neutrophil-Lymphocyte Ratio with Efficacy in Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Lenvatinib
    Taylor, Matthew H.
    Takahashi, Shunji
    Capdevila, Jaume
    Tahara, Makoto
    Leboulleux, Sophie
    Kiyota, Naomi
    Dutcus, Corina E.
    Xie, Ran
    Robinson, Bruce
    Sherman, Steven
    Habra, Mouhammed Amir
    Elisei, Rossella
    Wirth, Lori J.
    THYROID, 2021, 31 (08) : 1226 - 1234
  • [40] Molecular Theranostics in Radioiodine-Refractory Differentiated Thyroid Cancer
    Ovcaricek, Petra Petranovic
    Campenni, Alfredo
    de Keizer, Bart
    Deandreis, Desiree
    Kreissl, Michael C.
    Vrachimis, Alexis
    Tuncel, Murat
    Giovanella, Luca
    CANCERS, 2023, 15 (17)
12345